Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant +/- Anastrozole in Presurgical Breast Cancer
NCT00259090Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2004
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fulvestrant in breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoints: Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score, Percentage Change From Baseline to Time of Surgery in Progesterone Receptor (PgR) H-score and 1 more. Started Apr 2004; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00259090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00259090.